One shot instead of two? new IV iron aims to simplify anemia treatment

NCT ID NCT07687784

Not yet recruiting Disease control Sponsor: AFT Pharmaceuticals, Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 07, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This phase 3 trial tests whether a single infusion of a new intravenous iron, Ferric Bepectate, can raise hemoglobin as effectively as two infusions of the current standard treatment (ferric carboxymaltose) in adults with iron deficiency anemia. About 1,366 participants will receive either one or two doses of the new drug or two doses of the standard drug, and their blood levels will be monitored over six weeks. The study also tracks side effects to compare safety.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Ferric Bepectate (intravenous iron)
What this could lead to: If successful, this could offer a simpler, single-dose IV iron treatment for iron deficiency anemia, reducing clinic visits.
What could go wrong: This is a non-inferiority trial, so the new drug may prove no better than existing options. As with any IV iron, there is a risk of allergic reactions or infusion-related side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for IRON DEFICIENCY ANEMIA (IDA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

iron deficiency anemia

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IRON DEFICIENCY ANEMIA (IDA)

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.